FDA reverses course, will review Moderna’s flu vaccine application

Moderna said today the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling drugmaker and investor concerns over policy changes at the agency under President Donald Trump.